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Abstract: We have compiled from literature and other sources a list of 1261 proteins believed to be differentially expressed 
in human cancer. These proteins, only some of which have been detected in plasma to date, represent a population of can-
didate plasma biomarkers that could be useful in early cancer detection and monitoring given sufﬁ  ciently sensitive speciﬁ  c 
assays. We have begun to prioritize these markers for future validation by frequency of literature citations, both total and 
as a function of time. The candidates include proteins involved in oncogenesis, angiogenesis, development, differentiation, 
proliferation, apoptosis, hematopoiesis, immune and hormonal responses, cell signaling, nucleotide function, hydrolysis, 
cellular homing, cell cycle and structure, the acute phase response and hormonal control. Many have been detected in studies 
of tissue or nuclear components; nevertheless we hypothesize that most if not all should be present in plasma at some level. 
Of the 1261 candidates only 9 have been approved as “tumor associated antigens” by the FDA. We propose that systematic 
collection and large-scale validation of candidate biomarkers would ﬁ  ll the gap currently existing between basic research 
and clinical use of advanced diagnostics.
Keywords: cancer, biomarkers, targeted proteomics, validation.
Abbreviations: MS mass spectrometry; GO Genome Ontology. 
Introduction
The study of cancer biomarker proteins began in 1847 with the discovery by Henry Bence-Jones of 
what turned out, more than 100 years later, to be a tumor-produced free antibody light chain “Bence 
Jones protein” in the urine of a multiple myeloma patient (Bence-Jones 1847; Kyle 1994) where it 
was present in large quantities and could be revealed by simple heat denaturation. One hundred and 40 
years later this protein was demonstrated to be present also in the serum (Sinclair et al. 1986), and in 
1998 a routine immunodiagnostic test was approved by the FDA. Hormones produced by tumors were 
also detected early on (Chan and Sell 1999): adrenocorticotropic hormone (ACTH), calcitonin, and 
chorionic gonadotropin (hCG), for example, are elevated in speciﬁ  c cancer types, though not with the 
tumor speciﬁ  city of Bence-Jones proteins.
Unfortunately, the paradigm in which an overproduced tumor-speciﬁ  c protein can be easily detected 
as a marker of cancer has turned out to be the exception rather than the rule: in the nearly 160 years since 
Bence-Jones’ discovery, less than 10 proteins have progressed to the level of FDA-approved cancer 
diagnostic tests, and most of these lack ideal sensitivity and speciﬁ  city for cancer. 
In recent years “… the emerging science of genomics and proteomics have generated a plethora of 
candidate cancer biomarkers” (Pritzker 2002). Unfortunately few of these markers immediately stand 
out as superior prognostic or diagnostic tools, and even fewer have been validated and approved. 
Several factors might account for the slow pace of advance in cancer biomarkers. On the one hand, 
available proteomics technology has limited power to detect low-abundance cancer biomarkers against 
the background of high-abundance plasma proteins, and many of the best markers may thus be missed 
until discovery technology improves. On the other hand, the capacity to verify and validate existing 
candidate markers (through rigorous testing in large sample sets from many diseases) is limited, and it 
is therefore possible that the required biomarkers have already been “discovered” but not yet validated. 
In this paper, we are concerned with the latter possibility, and speciﬁ  cally with the problem of selecting 
among the existing candidates those that are most promising for systematic validation.
This line of enquiry immediately raises the question: where is the list of known candidate cancer 
biomarkers? While a number of useful reviews and books discuss speciﬁ  c cancer markers with clinical 
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promise, these generally concentrate on proven, 
or at least well-developed, markers or speciﬁ  c 
disease states. We were unable to ﬁ  nd a list that 
draws together a large population of candidates at 
all stages of development from multiple discovery 
sources, and thus our ﬁ  rst step has been to create 
one through a combination of literature search and 
other methods. 
The value of a list of existing candidates could 
be limited by the general lack of sensitivity and 
speciﬁ  city exhibited by most of the cancer markers 
found to date, a factor that may have discouraged 
others from undertaking this task previously. Most 
candidates that have been followed up in larger 
studies have shown poor diagnostic value (Table 1), 
and even those that have been approved for clinical 
use exhibit lower sensitivity and speciﬁ  city than 
the well-known markers of, eg, acute cardiovas-
cular events (ie, troponin in myocardial infarction 
or B-type natriuretic peptide in congestive heart 
failure, Table 1).
On the other hand, there seems to be a growing 
consensus that panels of markers may be able to 
supply the speciﬁ  city and sensitivity that individual 
markers lack. For example a panel combining four 
known biomarkers (leptin, prolactin, osteopontin, 
insulin-like growth factor II), none of which used 
alone could distinguish patients from the controls, 
achieved a sensitivity and speciﬁ  city of 95% for 
the diagnosis of ovarian cancer (Mor et al. 2005). 
In this case a combination of known proteins in a 
novel panel provided a signiﬁ  cant advance. Xiao
et al. identiﬁ  ed 299 proteins in tissue culture by 1-D 
page and nano-ESI-MS/MS but then used ELISA 
to test 13 of the most interesting in serum. They 
reported that CD98, fascin, the secreted chain of 
the polymeric immunoglobulin receptor and 14-3-3 
eta provide greater sensitivity when used together 
Table 1. Example sensitivities and speciﬁ  cities for the nine FDA approved cancer biomarkers.
Marker Disease  Cut  Off  Sensitivity  Speciﬁ  city  Reference
CEA malignant  pleural  effusion  NA
1  57.5%  78.6%  (Li et al.  
           2003)
CEA  peritoneal cancer   0.5 ng/ml  75.8%  90.8%  (Yamamto
  dissemination        et al. 2004)
Her-2/neu  stage IV breast cancer  15 ng/mL   40%   98%
2   (Cook et al. 
         2001)
Bladder Tumor Antigen  urothelial cell carcinoma   NA  52.8%   70%  (Mian et al. 
         2000)
Thyro-globulin  thyroid cancer metastasis  2.3 ng/ml
3   74.5%   95%  (Lima et al.
           2002)
Alpha-fetoprotein  hepatocellular carcinoma  20 ng/ml  50%  70%  (De Masi 
         et  al.2005)
PSA  prostate cancer  4.0 ng/mL  46%  91%  (Gann et al.
         1995)
CA 125  non-small cell lung cancer  95 IU/mL  84%  80%  (Dabrowska  
          et al. 2004)
CA19.9  pancreatic cancer  NA  75%  80%  (Yamaguchi  
          et al. 2004)
CA 15.3  breast cancer  40 U/ml  58.2%  96.0%  (Ciambellotti
          et al. 1993)
leptin, prolactin,  ovarian cancer  NA  95%  95%  (Mor et al.
osteopontin, and IGF-II          2005)
CD98, fascin, sPIgR
4,   lung cancer  NA  96%  77%  (Xiao et al.
and 14-3-3 eta          2005) 
Troponin I  myocardial infarction  0.1 microg/L  93%  81%  (Eggers 
         et  al.2004)
B-type natriuretic  Congestive heart failure  8 pg/mL  98%  92%  (Dao et al.
peptide         2001)
1. Not available
2. vs benign breast diseases 
3. vs 3rd week post surgery
4. Secreted chain of the polymeric immunoglobulin receptor 
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as a panel than any of the markers used alone (Xiao 
et al. 2005). 
If, as we and others (Conrads et al. 2003) 
believe, panels of proteins provide the most 
promising avenue towards early and accurate 
cancer detection, then a re-examination of known 
candidates provides a logical approach to panel 
generation, with the expectation that a stream of 
new markers can be added as they are identiﬁ  ed 
by marker discovery studies. This candidate-based, 
or targeted, approach will require a comprehensive 
list of prioritized candidates coupled with a tech-
nology able to assay these in large sets of plasma 
and serum samples from clinical and epidemio-
logical studies (together a “biomarker pipeline” 
(Anderson 2005b)). 
Here we have begun to compile and prioritize 
a database of candidate biomarkers reported to be 
differentially expressed in studies of human cancer. 
We have included changes observed either at the 
protein (plasma or tissue) or nucleic acid (tissue 
DNA or RNA) level for any cancer, and excluded 
results restricted to animal, cell culture systems, or 
single case report studies in hopes of focusing on 
the most promising clinical biomarker candidates. 
We hypothesize that the protein version of most, 
if not all of these markers should be detectable in 
blood plasma at some level, irrespective of the 
tissue source, ultimately allowing for their use in 
patient screening, diagnosis or follow-up.
Experimental Procedures
Search strategy 
The principal strategy for creation of our list
involved compilation of designated cancer related 
proteins from: our previously published work
(Anderson et al. 2004), PubMed literature searches, 
cancer microarrays (868 proteins from 111 hu-
man cancer Superarrays (http://www.superarry.
com and in supplemental material), Circulating
Tumor Markers of the New Millennium (Wu 2002), 
American Association for Clinical Chemistry 
abstracts and general literature perusal. PubMed 
searches included de novo PubMed literature 
searches: [plasma (Title/Abstract) NOT membrane 
(Title/Abstract) NOT stimulation (Title/Abstract) 
NOT drug (Title/Abstract) NOT dose (Title/Ab-
stract) AND protein (Title/Abstract) AND cancer] 
and [“cancer antigen” AND human], as well as 
the PubMed literature search used for proteins 
from other sources [“protein name” AND cancer 
AND human AND (where necessary) diagnostic 
AND (where necessary) expression] and PubMed 
“related article” searches. Only proteins for which 
we found at least one published study on human 
cancer utilizing primary samples were retained 
(639 of the array proteins). Each biomarker refer-
ence was then manually tabulated and curated as 
to disease and tissue (including plasma). Single 
case studies were excluded. 
Clinical use data
FDA approval dates for tests were obtained from 
the FDA Center for Devices and Radiological 
Health database. Proteins designated here as 
clinical markers are those offered commercially by 
ARUP or by Mayo Medical Laboratories, or else 
offered for internal use by either NIH or the Fred 
Hutchinson Cancer Research Center.
Citation analysis 
Each documented protein on the resulting list was 
searched against the literature (via PubMed) us-
ing the query [“protein name” AND human AND 
cancer AND diagnostic]. This is admittedly a crude 
metric of research interest in a biomarker, but 
provides a useful method of relative prioritization 
among markers. In tabulating citation frequen-
cies we did not exclude those categories ruled out 
in compiling the list initially: studies of animal 
systems, single clinical cases, or cell lines. If 
the “protein name” was not found by this search 
strategy it was counted as zero. It must be noted 
that PubMed is not a static archive but rather con-
stantly changing both by additions, subtractions, 
and redefinition of MeSH headings. Still this 
exercise allowed some relative ranking of interest 
and therefore importance. Total cancer citations 
per year were determined using the query [human 
AND cancer AND diagnostic] limited to a speciﬁ  c 
publication year.
Annotation 
Swiss-Prot/Uniprot accession numbers were 
obtained where possible. Most of the TrEMBL 
annotations were done prior to the addition of 
species information to the annotation number and 
so this form of the annotation was maintained. 
Candidate cancer biomarkers were annotated with 
GO numbers and IDs from EBI’s human GOA 30.0 
Biomarker Insights 2006:14
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(gene_association.goa_human, ftp://ftp.ebi.ac.uk/
pub/databases) and the Gene Ontology’s GO.def 
version 1.213 (http://www.geneontology.org/ontol-
ogy/GO.defs) respectively. Similar ID groupings 
were then combined. The entire Human GO ﬁ  le 
was treated in an identical fashion for comparison 
with the candidates.
Protein concentrations
Where possible, normal or control values for the 
plasma concentration of each protein were obtained 
by literature search. Unless speciﬁ  cally noted, 
protein concentrations are for the intact protein 
not individual subunits.
Results
A search strategy combining literature search, 
extraction from microarray data, and a review of 
existing clinical tests, followed by manual cura-
tion, provided a list of 1261 candidate protein 
biomarkers (supplemental material) for which we 
found evidence of a quantitative change in some 
human cancer. As shown in Table 2, the candidates 
included proteins known to occur in plasma (274), 
proteins detected in tissue samples (542), and pro-
teins whose corresponding mRNA or DNA levels 
were differentially expressed between cancerous 
and normal samples (656). These categories are 
non-exclusive in that a signiﬁ  cant number of the 
candidates were found in more than one type of 
study. Proteins detected in the plasma represent 
22% of the total proteins documented to date.
Citation frequency
Citation frequency analysis was used as one method 
of prioritizing the biomarkers, on the assumption 
that proteins most widely studied in the context of 
cancer had more promise as biomarkers. Citation 
frequency was determined using a PubMed query 
intended to count citations in which the authors 
considered the proteins to have diagnostic value 
(Figure 1, Table 3). When this is done, 29% of the 
1,261 biomarkers have no such citations, 67% have 
fewer than 10, and 74% fewer than 20. Likewise 
only a very limited number of biomarkers have 
extensive citations, 62 proteins or only 5% of the 
total number of biomarkers were found to have 
greater than 500 citations. 
Biomarkers with greater 
than 500 citations
Of the 34 biomarkers with more than 1000 citations 
(Figure 2, Table 3) 79% are found in the plasma 
and 56% are presently used clinically (89% of 
which are reported in plasma). Of the 28 markers 
with between 500 and 1000 citations (Figure 3) 
57% are plasma proteins but only 7% are used 
clinically. Both of the markers used clinically are 
plasma proteins. Some proteins with high citation 
frequency (eg, albumin) are somewhat surprising to 
see in the context of cancer biomarkers; these have 
been retained nevertheless because they appear to 
have reasonable relevance (low serum albumin 
Figure 1. Biomarker Citation Frequency. Citation Frequency for 
each protein was determined using the PubMed query [“protein 
name” AND human AND cancer AND diagnostic]. Proteins were then 
histogrammed in bins of 10, 100 and 1000 citations (for frequencies 
of n<100, 100<n<1000, and n>1000, respectively) and each bin’s 
count normalized through division by bin size (eg the count of proteins 
falling in the 11-20 citations bin was divided by 10).
Table 2.  Distribution of cancer biomarkers.  Other = amniotic, bile, cerebrospinal ﬂ  uid, follicular ﬂ  uid, milk of 
lactating women, pancreatic ﬂ  uid, seminal plasma, sputum, stools and urine.
1261 Unique proteins  Proteins in plasma  Tissue proteins  DNA & RNA data  Other
Proteins in plasma  274  60  24  6
Tissue proteins  60  542  152  6
DNA & RNA data  24  152  656  3



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Malu Polanski and N. Leigh Anderson
levels are prognostic of poor survival (Lis et al. 
2003) as noted in the table contents).
Proteins with a large number or 
percentage of citations in 2004 
In an effort to include more recently discovered 
biomarkers we also looked at the proteins that had 
greater than 100 citations in 2004 or greater than 
50% of their citations in 2004. Of the proteins with 
more than 100 citations in 2004, all but COX2 
are represented in ﬁ  gures 2 and 3. Of those with a 
majority of total citations occurring in 2004, most 
have a low number (<10) of absolute citations 
(Figure 4, Table 3), 32% are detected in plasma 
and none are presently being used clinically.
Time evolution of biomarker
citations
We tracked the number of citations per year for 
selected cancer biomarkers over the last 35 years 
(Figure 5). The number of times a protein was cited 
in a given year (“protein name” AND cancer AND 
human AND diagnostic) was divided by the total 
number of cancer citations for that year (cancer 
AND human AND diagnostic) to give a rough in-
dex of the prominence of the biomarker in cancer 
research. Although frequently cited in the 1970’s 
and 1980’s, interest in CEA has dropped dramati-
cally. The most cited marker in this group, PSA, 
has well-documented limitations as a diagnostic 
yet it continues to be cited either as the only op-
tion or as the biomarker upon which to improve. 
Interest in most of these biomarkers evolves in a 
Figure 2. Proteins with greater than 1000 citations in Fig 1. White 
bars indicate non plasma proteins not used clinically, light gray bars 
indicate clinically used proteins not yet detected in plasma, dark 
gray bars indicate plasma proteins not used clinically and black 
bars indicate plasma proteins used clinically. CEA = Carcinoembry-
onic Antigen, PSA = Prostate Speciﬁ  c Antigen, ER alpha = Estrogen
Receptor alpha, LH  =  Luteinizing Hormone, PR  =  Progesterone 
Receptor, PCNA = Proliferating Cell Nuclear Antigen, FSH = Follicle-
stimulating Hormone, NSE = Neuron-speciﬁ  c enolase, PH = Parathy-
roid Hormone.
Figure 3. Proteins with greater than 500 but less than 1000 cita-
tions in Fig. 1. White bars indicate non-plasma proteins not used 
clinically, dark gray bars indicate plasma proteins not used clinically 
and black bars indicate plasma proteins used clinically. Beta-2-
MG = Beta–2-microglobulin,  IFN-gamma = IFN-gamma,  CRP = C 
reactive  protein,  CGA = Chromogranin  A,  EPN = Erythropoietin, 
VWF = Von Willebrand Factor.
Biomarker Insights 2006:135
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fairly similar way: each appears to take a few years 
to be recognized, followed by gradually increas-
ing interest over the following 15 to 20 years. Of 
these markers the FDA has approved only three 
as diagnostic cancer antigens: alpha-fetoprotein, 
CEA, and PSA (approved May 31, 1988, October 
15, 1980 and February 25, 1986 respectively; 
Figure 5). To date only 6 additional markers have 
been approved by the FDA under the category of 
tumor associated antigens: CA 19-9 in May of 
2002, Her2/Neu in September of 2000, CA 15.3 
in February of 1981, bladder tumor marker in 
April of 1997, thyroglobulin in March of 1999 and 
CA 125 in July of 1987 (Table 4). None of these 
markers, used singly, has over 90% sensitivity and 
speciﬁ  city. Although these numbers are for speciﬁ  c 
assays, they are representative of the general lack 
of speciﬁ  city and sensitivity of the individual can-
cer markers currently available.
Concentration range of cancer 
plasma biomarkers
We attempted to collect normal plasma concen-
trations for candidate cancer biomarkers reported 
in the literature. The resulting 211 values were 
histogramed (Figure 6) for comparison with the 
distributions of concentrations of either unselected 
plasma proteins from PPI’s plasma protein data-
base, or a set of candidate cardiovascular biomark-
ers (Anderson 2005a). The cancer candidates cover 
Figure 4. Proteins of “recent” interest (more than 50% of Fig. 1., 
citations occurring in 2004). White bars indicate non-plasma proteins 
not used clinically, dark gray bars indicate plasma proteins not used 
clinically. MG B = Mammaglobin B, HG = Haptoglobin 1, S-gamma = 
Synuclein-gamma, NESP-55 = Neuroendocrine secretory protein-55, 
CDK-6 = Cyclin-dependent kinase 6, 17betaHD1 = 17 beta-Hydroxys-
teroid dehydrogenase type 1.
Figure 5. Evolution of Marker Interest. The number of times a marker is cited in a particular year divided by the total number of cancer cita-
tions for that year. Solid gray stars designate when the FDA approved CEA, PSA and alpha-fetoprotein. CEA = Carcinoembryonic Antigen, 
PSA = Prostate Speciﬁ  c Antigen, PDGRFR = Platelet-derived Growth Factor Receptor alpha.
Biomarker Insights 2006:136
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a >10-log concentration range with proteins such as 
immune modulating interleukins (1α and β, 2, 5, 6, 
9, 10, IFN-γ and GM-CSF) being present in normal 
plasma or serum in the pg/mL range while classical 
plasma proteins (albumin, transferrin, ﬁ  brinogen, 
and α-2-macroglobulin) are present at mg/mL 
levels. When the cancer candidate distribution 
is compared to the concentrations for all plasma 
proteins (unpublished results) and plasma mark-
ers of cardiac disease, a greater proportion of the 
cancer candidates appear in the lower concentra-
tion ranges than general plasma proteins or cardiac 
markers. Thus normal values for 185 (88%) of the 
markers for which we know the plasma concentra-
tion fall below 10 microgram/mL and 103 (49%) 
fall below 10 ng/mL. Tabulated concentrations are 
those found in controls not patients. Thus in many 
cases these may increase in cancer, thereby aiding 
in their detection.
Genome Ontology classiﬁ  cation of 
cancer candidate biomarkers
We compared the distribution of GO annotations 
for the cancer candidates with the distribution for 
all annotated human proteins over a series of sum-
mary categories, with the aim of ﬁ  nding any large 
biases in the cancer group. In comparing “Biologi-
cal Process” GO annotation, the cancer biomarkers 
show an increased representation of apoptosis, 
cell cycle and proliferation annotations; processes 
blocked or increased in tumors (Figure 7); while 
metabolism, catabolism and transport proteins are 
decreased. When the two sets are compared by 
“Cellular Component” GO terms (Figure 8), the 
extracellular category is over represented in the cancer 
biomarker database in comparison with the whole 
human database (20% versus 6% respectively). This
is true even if the proteins found experimentally
Figure 6. Distribution of Normal Plasma Concentrations for Plasma 
Cancer Biomarkers. The number of plasma concentrations falling 
within a given log of pg/ml were normalized to percent of total and then 
were histogrammed in log bins. The concentrations of the 211 cancer 
biomarkers detected in plasma are represented by the solid line, the 
concentrations of the unselected plasma proteins by the dashed line, 
and the concentration of cardiac biomarkers by the dotted line.




in plasma are excluded (12% extracellular). 
The other Cellular Component categories show 
only small differences between the proteins sets. 
Comparing “Molecular Function” GO terms, 
only small differences are apparent between the 
cancer candidates and the whole annotated human 
proteome. 
Prioritization of candidates
Given the size of the list of candidates resulting 
from our assembly procedure, we attempted to 
select a smaller subset of higher priority candi-
dates as a starting point for consideration of assay 
development and clinical validation. This subset 
comprising 260 proteins (Table 3) was compiled 
from the most highly cited proteins, the “recent” 
markers, plasma proteins of known concentration 
(indicating existence of an assay) and any marker 
presently in any type of clinical use. Many of 
these markers fall into expected categories such 
as immune modulation molecules (acute phase 
proteins, coagulation factors, immune modula-
tors); and mediators of classical cancer pathways 
(oncoproteins, angiogenic or apoptosis factors, 
tumor suppressors or antigens, cellular homing
or proliferation molecules). Somewhat less
expected perhaps is that almost 22 (8%) of these
top 262 proteins are involved in hormonal
action.
Existence of a speciﬁ  c antibody
For each of the 260 high priority candidates, we 
performed web searches, primarily through the 
Exact Antigen website (www.exactantigen.com), 
to determine whether an antibody with potential 
utility in a plasma assay is commercially available. 
Relevant antibodies were found for 186 (72%) of 
the 260 high priority candidates.
Discussion
According to the Centers for Disease Control, 1 
in every 4 deaths in the United States is due to 
cancer. Many of these deaths could be averted 
by improved early cancer detection, since exist-
ing therapies, especially surgery, are much more 
effective in early cancer stages as compared to 
later stages (Etzioni et al. 2003). Billions of dol-
lars have been spent on basic research looking for 
molecular differences related to cancer-work that 
has been at least partly motivated by the need for 
improved in vitro diagnostic tests to detect or moni-
tor progression of cancer. Yet to our knowledge no 
centralized database of known candidate cancer 
biomarkers exists. Such a list could serve to con-
ﬁ  rm new results, eg, from proteomic comparisons 
of cancer and control sera, by placing them in a 
context of earlier work. Additionally it could serve 
as a reservoir of current and future candidates to 
be tested in large sample sets by candidate-based 
Figure 8. Distribution by Cellular Component. Genome Ontology categories for A) Cancer biomarker proteins, B) Overall human proteome 
(genome data).
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(“targeted” or “directed”) proteomics methods. 
The latter use is important, since candidate-based 
methods, consisting of speciﬁ  c assays for deﬁ  ned 
targets, are likely to be much more sensitive than 
proteome proﬁ  ling methods, and hence could cover 
a much broader universe of protein candidates and 
potentially detect disease states earlier. 
The present catalog of 1261 human candidate 
cancer biomarkers is a ﬁ  rst attempt at such a da-
tabase. We did not select speciﬁ  c cancer types or 
speciﬁ  c detection methods, choosing instead to cast 
a broad net. In the resulting list, it will be appar-
ent that the strength of evidence and likelihood of 
ultimate usefulness of the candidates varies widely. 
Even candidates that have been tested and found 
to have poor diagnostic speciﬁ  city and sensitivity 
were retained, as they may nevertheless contribute 
to useful panels as in the work of Mor and Xiao. 
Looking at the list, one might question why the 
most abundant plasma protein (serum albumin) is 
included – though perhaps counter-intuitive, albu-
min does meet the search criteria used, and is in 
fact a useful negative acute phase indicator likely 
to be altered in cancer along with many inﬂ  amma-
tion-related proteins. Other well-known proteins 
not usually considered as cancer-speciﬁ  c are also 
included (eg, protein and peptide hormones over-
produced by endocrine tumors or through ectopic 
synthesis). Overall, the list is not easily recogniz-
able by inspection as a list of cancer markers. 
 Of the 1261 proteins, 22% are reported to occur 
in plasma. This is an appreciable fraction consider-
ing that many of the large array studies, capable 
of ﬁ  nding many markers per experiment, have 
looked for differential protein or DNA expression 
in tissues. For bona ﬁ  de cell-associated cancer 
markers such as Her-2, there is persuasive evidence 
that at least a fragment of the protein molecule is 
released into the plasma and can be detected as 
a cancer biomarker (Tse et al. 2005), and other 
proteins documented here in the tissues of cancer 
patients have been demonstrated to be found in 
plasma in other disease indications. These cases 
provide some support for the hypothesis that most 
if not all of the 1261 proteins should be detectable 
at some level in plasma, the diagnostic sample of 
choice, given a sensitive enough assay. Whether 
current assay technologies will be sensitive enough 
to see a large fraction of the candidates in plasma 
is a major question at this point, and one that will 
require vigorous efforts to resolve. 
As might be expected, there is a smooth dis-
tribution in the number of literature citations per 
candidate, ranging from almost 8,000 (for PSA) to 
zero (for candidates not mentioned as diagnostic 
by the publication’s authors). This result suggests 
that our literature analysis did not identify a crisply 
deﬁ  ned set of cancer markers, but rather part of 
a continuum extending from a few established 
markers through plausible candidates into more 
speculative possibilities. Given the complexity of 
cancer, such an outcome is not surprising. 
Only 5% of the 1261 candidates have been 
extensively studied (500 or greater total citations 




over the years). When examined as a function of 
time, the citation history of individual markers 
appears to show a slow evolution of interest that 
peaks 15 to 20 years after the initial papers. Only 
in the cases of CEA and PSA was discovery of a 
biomarker followed by a rapid increase in publi-
cations over a few years and in the case of PSA 
the steady increase was seen only 10 years after 
the ﬁ  rst citations appeared. Thus in order to catch 
recently emerged candidates, we focused on candi-
dates with a high proportion of citations occurring 
in 2004 but with fewer total citations (often 10 or 
less). Of the total 1261 proteins only 41 are used 
in some clinical sense and even fewer have FDA 
approved assays. 
While the observed slow pace is easily ex-
plained by the deliberate nature of clinical research 
and the progressive, rather than abrupt, nature of 
adoption in medical practice, it presents a stark 
reminder of the challenge involved in making any 
rapid advance in cancer diagnostics.
These candidate cancer markers, taken as a 
group, appear to be present in plasma at lower 
concentrations than comparable groups of cardiac 
markers or unselected plasma proteins. Although 
systematic biases in selection of these groups could 
affect this result, it tends to support the contention 
that plasma cancer marker discovery is, and may 
continue to be, a challenge in terms of detection 
sensitivity. Present discovery proteomics platforms 
typically detect proteins with plasma concentrations 
in the mg/mL to microg/mL range. For the proteins 
in our list with known plasma concentrations, we 
estimate that 86% would be missed by most con-
ventional proteomics platforms, while 48% would 
be missed by high-end proteomics platforms with 
extensive multi-dimensional fractionation. For the 
present, the only way that many of these proteins 
can be detected is by speciﬁ  c assays: ie, by targeted 
proteomics. Targeted proteomics thus represents 
a preferred path to validation and further study of 
the candidate markers listed here.
The distribution of our cancer biomarker can-
didate proteins among GO annotation categories 
shows remarkable similarity to the distribution for 
all annotated human proteins. There is some enrich-
ment for proteins annotated as related to apoptosis, 
cell cycle and proliferation (in the GO biological 
process category), as would be expected on account 
of the fundamental involvement of these processes 
in cancer. The extracellular group (in the GO cell 
component category) is also somewhat over-rep-
resented, a trend favorable to detection in plasma. 
Nevertheless the candidates seem to represent a 
very wide sampling of the human proteome. 
The full set of these 1,261 candidates is too large 
to submit for immediate veriﬁ  cation and validation 
in large sample sets by any available means, and 
some method of prioritization is required to initiate 
their evaluation. As an initial approach, we have 
selected a subset of the candidates based on a set of 
criteria including number of total citations, number 
of recent citations, proportion of recent citations, 
known plasma concentration (implying existence 
of an assay) and clinical use in any context. This 
subset of 260 candidates (presented in Table 3) 
includes 186 candidates for which a relevant 
antibody is commercially available, opening the 
possibility of testing this group using an antibody 
array or other miniaturized immunoassay technol-
ogy in the near future. 
While the list of candidate cancer biomarkers 
assembled here is clearly a simplistic and there-
fore somewhat crude initial catalog, we believe 
the result will prove to be of sufﬁ  cient value to 
justify extending the effort to provide an ongoing 
summary of the progress of cancer diagnostics. 
In particular we believe that linking a database 
of marker candidates to the bioinformatics ar-
chitecture used in biomarker discovery will help 
to connect the discovery and validation phases 
(Anderson 2005b) necessary for progression of 
biomarkers to the clinic. One can envision a steady 
accumulation of candidates, regular revision of 
candidate priorities as evidence emerges from 
multiple sources (literature, microarrays, systems 
models, etc), and ﬁ  nally feedback in the form of 
speciﬁ  c measurements from validation studies in 
large sample sets. Such a collection of data would 
provide an up-to-date snapshot of the workings of 
a cancer diagnostic marker pipeline. 
Finally, lists such as this prompt important, 
but infrequently-asked questions regarding the 
most productive tack for future discovery ef-
forts. Is it reassuring to ﬁ  nd conﬁ  rmation of fresh 
observations through overlap with a pre-existing 
list? Perhaps so, and particularly if the candidates 
involved appear repeatedly in similar independent 
studies. However the sieve used here is crude and 
so our list cannot really “conﬁ  rm” a candidate seen
in a new study–overlap just improves the odds of 
relevance. Further, since there are certain to be 
good cancer markers not on this list, failure to ap-
pear here in no way disqualiﬁ  es a novel marker. 
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Hence our hope is to contribute a mechanism for 
marginally improving chances of recognizing a 
valid marker, and a systematic source for enriched 
candidates available for validation and panel as-
sembly efforts.
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